Do you want to read an article? Please log in or register.
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)
Macular Diseases
COMMENTED
Related content
Macular Diseases
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T
Curr Opin Ophthalmol.
Cai S, Bressler NM
doi: 10.1097/
COMMENTED
Macular Diseases
Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial
JAMA Ophthalmol.
Bressler NM, Odia I, Maguire M, Glassman AR, Jampol LM, MacCumber MW, Shah C, Rosberger D, Sun JK, DRCR Retina Network.
doi: 10.1001/jamaophthalmol.
Macular DiseasesRetinal Diseases
Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema: A Subanalysis of the RESTORE (Extension) Study
JAMA Ophthalmol.
Karst SG, Deak GG, Gerendas BS, Waldstein SM, Lammer J, Simader C, Guerin T, Schmidt-Erfurth UM
doi: 10.1001/jamaophthalmol.
Macular Diseases
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial
JAMA Ophthalmol.
Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network
doi: 10.1001/
RECOMMENDED
Macular Diseases
Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry
★ 3
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
★ 3
Recommended by
Prof. Dr Ke Yao, Faculty Member
Ophthalmology.
Bhandari S, Nguyen V, Fraser-Bell S, Mehta H, Viola F, Baudin F, Gabrielle PH, Creuzot-Garcher C, Gillies M, Barthelmes D
doi: 10.1016/j.ophtha.2019.11.018.
Macular Diseases
Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes with Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study
JAMA Ophthalmol.
Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Ghuman T, Baker CW; SCORE2 Investigator Group
doi: 10.1001/jamaophthalmol.
COMMENTED
Macular Diseases
Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial
JAMA Ophthalmol.
Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Hounsome B, Yang Y, Harding SP, Lotery A, Chakravarthy U, Sivaprasad S, LEAVO Study Group.
doi: 10.1001/
Macular Diseases
Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab
Clin Exp Ophthalmol.
Spooner K, Fraser-Bell S, Hong T, Chang A
doi: 10.1111/ceo.13636.
COMMENTED
Retinal Diseases
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial
JAMA Ophthalmol.
Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, Bressler NM, Elman MJ, Ferris FL 3rd, Gardner TW, Jampol LM, Martin DF, Melia M, Stockdale CR, Beck RW, Diabetic Retinopathy Clinical Research Network
doi: 10.1001/jamaophthalmol.